The amine-borane adducts of cyclohexylamine and toluidine were observed to be potent hypolipidemic agents in mice, I.P. and rats orally at 8 mg/kg/day lowering both serum cholesterol and triglyceride levels after 14-16 days. These compounds were able to lower tissue lipids including the cholesterol content of the aorta wall. The agents successfully lower VLDL-and LDLocholesterol content while elevating HDL-cholesterol content significantly. The agents also modulate lipid regulatory enzyme activities in a manner to reduce liver lipid levels. These studies demonstrate that the nitrogen atom does not have to be apart of the aromatic ring as in heterocyclic-amine borane to afford good hypolipidemic activity in rodents.
INTRODUCTION
Previously we have examined a number of amine-cyanoboranes [l] aminecarboxyboranes and their amides and esters [2] [3] [4] [5] , di-and triopeptide boranes [6] , heterocyclic-amine boranes [7] , polyborate salts [8] , choline and thiocholine boranes [9] , phosphoacetate boranes[10] and deoxyribonucleoside cyanoboranes [ll] . These agents were effective in rodents at 8 mg/kg/day, significantly lowering both serum cholesterol and triglyceride levels after 14-16 days. Cholesterol levels were lowered in rat VLDL and LDL fractions while the HDL cholesterol levels were markedly elevated. The mode of action of these derivatives was to acclerate bile cholesterol excretion and alteration of regulatory enzyme activities involved in de novo lipid synthesis. Furthermore, sub-acute toxicity studies in mice indicated no organ specific toxicity and mean survival doses were high [12] . Thus, we have decided to examine a series cyano-and carboxyborane adducts of cyclohexylamine and toluidine for their hypolipidemic activity in rodents. These studies should determine if the nitrogen atom is necessary in the aromatic ring to maintain activity as a hypolipidemic agent in rodents.
MATERIALS and METHODS
Source of compounds All of the compounds were synthesized previously and chemically and physically charectezized [13] cyclohexylamine-cyanoborane _i, cyclohexylamine-carboxyborane 2, N-methylcyclohexylamine-carboxyborane 3_, N-ethylcyclohexylamine-carboxyborane 4 , N,N-dimethylcyclohexylaminecarboxyboranes 5, 2-methylcyclohexylamine-carboxyborane 6, 3-methylcyclohexylamine-carboxyborane 7, 4-methylcyclohexylaminecarboxyborane 8, N-ethylcyclohexylamine-cyanoborane 9, N-Vol. 2 , No. 4, 1995 Hypolipidemic Activity of Amine-Borane Aducts of Cyclohexylamine and Toluidine in Rodents methylcyclohexylamine-cyanoborane IO, N,N-dimethylcyclohexylaminecyanoborane ii, 2-methylcyclohexylamine-cyanoborane 12, 3- methylcyclohexylamii'e-cyanoborane 13, 4- 
Normolipidemic studies
For structure activity studies, CF I male mice (-28g) were administered amine-borane adducts of cyclohexylamine and toluidine in i CMC at 8 mg/kg/day, I.P. Blood samples were obtained on days 9 and 16 between 7"30 and 8"30 a.m. Daily dosing of the agents was between 9"00 and I0"00 a.m. the serum was obtained by centrifuging the blood for i0 min. at 3500 g. The serum cholesterol levels were determined by a modification of the procedure Lic.bermann-Burchard reaction [14] . Serum [16] [17] and the number of mg of lipid extracted was weighed. The lipid residue was taken up in methylene chloride and the levels of cholesterol [14] , triglycerides neutral lipids [18] and phospholipids [19] were determined. Protein content of the whole homogenate was determined [20] . [30] , s__n-Glycerol-3-phosphate acyl transferase activity was determined with s__n-glycerol-3ophosphate [L-2-3H(N)] (7.1 Ci/mmol) with the microsomal fraction of liver homogenates.
The reaction was terminated after 60 rain and the lipids were extracted with chloroform/methanol (2"1) containing i HCI and counted [31] .
Phosphatidylate phosphohydrolase activity was measured as inorganic phosphate released after 60 min [32] Table 2 ]. In rats at 8 mg/kg/day, compound 9 lowered serum cholesterol levels 32% after 14 days administration orally, whereas compounds _7 and 1__8 caused at 24-25% reduction. Nevertheless, these compounds were more potent Vol. 2, No. 4, 1995 Hypolipidemic Activity of Amine-Borane Aducts of Cyciohexylamine and Toluidine in Rodents [ 35] . The mode of action of the derivatives on regulatory enzyme activities involved in lipid metabolism appeared to be at site which regulated cytoplasmic formation of acetyl-CoA for cholesterol and fatty acid synthesis. These agents were not HMG-CoA reductase inhibitors whereas the heterocyclic amine-carboxy-and cyanoboranes were potent inhibitors. The amine-borane adducts of cyclohexylamine and toluidine accelerated cholesterol-7-hydroxylase activity more than the heterocyclic amine boranes. This would suggest that the former compounds probably accelerate the conversion of cholesterol to bile acids theoretically increasing cholesterol clearance from the body. These derivative marginally inhibited, acyl-cholesterol acyl transferase activity which should reduce cholesterol ester storage in tissues. In aorta walls this enzyme plays a role in depositing cholesterol esters in foam cells and increased plaque growth; thus inhibition of its activity should slow the process. It was hoped that the agents would accelerate cholesterol ester hydrolase activity. This enzyme breaks cholesterol esters down to free cholesterol which can be picked up by HDL to be conducted back to the liver via the reverse cholesterol transport mechanism for biliary excetion of cholesterol. This enzyme level is low in man but it is inducable by selective hypolipidemic agents to cause more clearnce of aorta wall lipids [36] . The heterocyclic amine-boranes were able to increase the activity of cholesterol ester hydrolaseo The neutral lipid and triglyceride pathways were inhibited by these derivatives at the site of phophatidylate phosphohydrolase, so that triglyceride can not be formed from phospholipids. The other regular enzyme of the triglyceride pathway, s__n-glycerol-3-phosphate acyl transferase, was marginally inhibited by compounds 9 and 18. These adducts were more potent in this respect than the heterocyclic amine boranes. Since hepatic lipoprotein lipase activity was also inhibited by the amine borane adducts of cyclohexylamine and toluidine, the inhibition of these three enzyme activities should be of a magnitude to lower triglyceride levels in the blood and tissue. Furthermore, some accelerated loss of triglycerides occurred in the feces, although bile excretion of triglycerides is considered to be of a small magnitude under normal conditions.
In conclusion, the amine-borane adducts of cyclohexylamine and toluidine maintain good hypolipidemic activity and achieve alteration in lipid metabolism and clearance which are desirable. Further investigation is warrented to evaluate such derivatives for clinical trails.
